Mutational Profiling in Epithelial Ovarian Cancer: A Meta-Analysis of 435 Patients Dataset

Data Description 0 represents no mutation, 1 represents a mutation Survive relates to the survival outcome of the patient. SurviveTime is in days (7300 chosen for alive patients). Ovarian Cancer Patients 435 count TP53, BRCA1, BRCA2, KMT2C, CDK12, CSMD3, TTN, MUC16, NF1, PALB2, RB1, PTEN, FOXM1, BRIP1, KRAS, RASA1, CHEK2, RAD50, RAD51C/D, MRE11A, NBN, FANCE, FANCD2, ATR, ATM, MSH2, PMS2, MLH1, MSH6, FAT1, FAT2, FAT3, FAT4 Uterine Cancer Patients 167 count FANCE, ATR, FAT3, MSH6, CDK12, CSMD3, FAT1, PMS2, BRIP1, FAT4, BRCA2, MUC16, PALB2, KRAS, TP53, PTEN, BRCA1, MSH2, KMT2C, NF1, ATM, FANCD2, NBN, CHEK2, MLH1 Cervical Cancer Patients 233 count MSH6, CSMD3, CDK12, FAT1, PMS2, BRIP1, RB1, FAT4, BRCA2, MUC16, PALB2, KRAS, TP53, PTEN, KMT2C, FAT3, BRCA1, NF1, ATM, FANCD2, NBN, ATR, MLH1, FANCE, CHEK2